Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia: Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002
- PMID: 16985626
- PMCID: PMC1473008
Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia: Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002
References
-
- Ulmert D, Becker C, Bjöork T, et al. Excellent stability of free and total PSA in EDTA-plasma after storage at −20°C for 25 years [abstract] Eur Urol. 2002:97.
-
- Djavan B, Zlotta A, Ravery V, et al. Prospective multicenter European study of complex PSA, CPSA, CPSAD, CPSA-TZ, C/total PSA ratio, C/free PSA ratio, F/T PSA, PSAD and PSA-TZ for early prostate cancer detection in men with PSA levels B [abstract] Eur Urol. 2002;1(suppl):98.
-
- Rowe E, Patel A, Walker M, et al. The utility of the free/total PSA ratio in prostate cancer detection in younger men aged 50-65 years with a ‘normal’ total PSA [abstract] Eur Urol. 2002;1(suppl):96.
-
- Bartsch G, Cheli CD, Babaian R, et al. Results of a multicenter prospective evaluation of complexed PSA [abstract] Eur Urol. 2002;1(suppl):99.
-
- Volgger H, Horninger W, Steiner H, et al. Consideration of low PSA levels to optimise the detection of curable prostate cancers: results of the Tyrol PSA screening project [abstract] Eur Urol. 2002;1(suppl):98.
LinkOut - more resources
Full Text Sources